In vitro podocyte experiments also showed the same results after treatment with AS-IV in the context of HG, demonstrating that AS-IV can alleviate DKD progression by regulating the SIRT6/HIF-1α/NLRP3 axis to inhibit podocyte pyroptosis [62]. This evidence concerns the gene NLRP3 and diabetic kidney disease.